Table 2.
Clinical and demographic variables in the two periods.
| First period (N = 408) | Second period (N = 277) | Difference | P | |
|---|---|---|---|---|
| Age | 66.57 (±15.51) | 71.09 (±16.65) | −4.52 (−6.96 to −2.08) | 0.003 |
| Age categorized | ||||
| <50 years | 15.20% | 11.91% | 0.106 | |
| 50–70 years | 38.73% | 33.94% | ||
| >70 years | 46.08% | 54.15% | ||
| Age >70 years | 80.03 (±7.13) | 84.45 (±7.03) | −4.43 (−5.95 to −2.90) | <0.0001 |
| Female | 157 (38.48%) | 128 (46.20%) | 7.73 (0.2–15%) | 0.0441 |
| Duration of symptoms prior to admission (days) | 7.01 (±4.99) | 7.82 (±7.28) | −0.81 (−1.76 to 0.15) | 0.096 |
| Hypertension | 43.87% | 50.90% | −7.03% | 0.07 |
| No prior pulmonary disease | 311 (76.23%) | 222 (80.14%) | 0.278 | |
| COPD | 37 (9.07%) | 28 (10.11%) | ||
| Emphysema | 11 (2.70%) | 6 (2.17%) | ||
| Other respiratory disease | 49 (12.01%) | 21 (7.58%) | ||
| Smoker | 62 (15.23%) | 33 (12%) | 3.23% (−2.08 to 8.5) | 0.23 |
| PaO2/FiO2 | 256.53 (±93.53) | 270.41 (±84.72) | −13.88 (−28.12 to 0.37) | 0.0563 |
| pCO2 | 34.42 (±7.55) | 36.27 (±8.20) | −1.85 (−3.10 to −0.61) | 0.0036 |
| PCR negative | 5 (1.23%) | 9 (3.25%) | 0.014 | |
| PCR positive | 367 (89.95%) | 229 (82.67%) | ||
| PCR negative but received treatment | 36 (8.82%) | 39 (14.08%) | ||
| Chest CT performed | 56 (13.73%) | 56 (20.22%) | 0.024 | |
| Bilateral pneumoniae | 77% | 68.61% | 0.0153 | |
| Ferritin (maximum) | 1520 (±93.77) | 1221 (±78.55) | 300 (53.19–546) | 0.0173 |
| Ferritin categorized (ng/mL) | ||||
| <500 | 23.88% | 29.93% | 0.139 | |
| 500–1000 | 24.48% | 25.91% | ||
| >1500 | 51.64% | 44.16% | ||
| Lymphocyte count (minimum) | 711 (±23) | 909 (±38) | <0.0001 | |
| IL-6 (maximum) | 679 (±126) | 194 (±46) | 484 | <0.0001 |
| IL-6 categorized (pg/mL) | ||||
| <50 | 46.93% | 58.26% | 0.002 | |
| 50–100 | 12.29% | 16.94% | ||
| >100 | 40.78% | 24.79% | ||
| Platelet count (maximum) | 187 (±5.37) | 204(±5.52) | −16.19 | 0.0421 |
| GPT | 123 (±19.69) | 68 (±5.45) | 54 | 0.0246 |
| LDH | 412 (±14.69) | 360 (±17.88) | 52.15 | 0.0243 |
| Troponin | 106.63 (±54) | 90(±50) | 16.32 | 0.8329 |
| D-Dimer | 3.59 (±0.294) | 3.39(±0.354) | 0.20 | 0.6564 |
| D-Dimer categorized (μg/mL) | ||||
| <0.5 | 10.03% | 17.19% | 0.028 | |
| 0.5–3.5 | 65.17% | 58.59% | ||
| >3.5 | 24.80% | 24.22% | ||
| Ceftriaxone | 83.74% | 77.97% | 5.76% | 0.0574 |
| Azythromycin | 95.57% | 97.11% | 1.53% | 0.3036 |
| Hydroxychloroquine | 89.18% | 87.72% | 1.46% | 0.5551 |
| Lopinavir/ritonavir | 23.82% | 1.80% | 22.02% | <0.0001 |
| Interferon | 32.01% | 11.91% | 20.82% | <0.0001 |
| Corticoids | 88.21% | 87.36% | 0.84% | 0.74 |
| No corticoids | 11.79% | 12.64% | 0.026 | |
| Methylprednisolone (Bolus) | 55.28% | 45.13% | ||
| Methylprednisolone (mg/kg) | 32.92% | 42.24% | ||
| Tocilizumab | 26.28% | 20.21% | 0.0674 | |
| Etoposide | 1.47% | 2.88% | 0.2004 | |
| Anakinra | 0.2457% | 1.01% | 0.0029 | |
| No anticoagulants | 7.37% | 4.69% | 0.322 | |
| Prophylactic anticoagulants | 61.67% | 65.34% | ||
| Therapeutic anticoagulants | 30.96% | 29.96% | ||